MDA-19

From Wikipedia, the free encyclopedia
Jump to: navigation, search
MDA-19
MDA-19 structure.png
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
Formula C21H23N3O2
Molar mass 349.426 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

MDA-19 is a drug that acts as a potent and selective agonist for the cannabinoid receptor CB2, with reasonable selectivity over the psychoactive CB1 receptor, though with some variation between species. In animal studies it was effective for the treatment of neuropathic pain, but failed to produce cannabis-like behavioural effects.[1][2]

See also[edit]

References[edit]

  1. ^ Diaz, Philippe; Xu, Jijun (2008). "Design and Synthesis of a Novel Series of N-Alkyl Isatin Acylhydrazone Derivatives that Act as Selective Cannabinoid Receptor 2 Agonists for the Treatment of Neuropathic Pain". J. Med. Chem. American Chemical Society. 51 (16): 4932–4947. doi:10.1021/jm8002203. PMID 18666769. 
  2. ^ Xu, JJ; et al. (Jul 2010). "Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain". Anesthesia and Analgesia. 111 (1): 99–109. doi:10.1213/ANE.0b013e3181e0cdaf. PMC 3253719Freely accessible. PMID 20522703.